UNSPSC 51142404: Dihydroergotamine

This classification denotes a nonnarcotic analgesic and dopamine agonist with the molecular formula C33H37N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 436O5HM03C, chemically known as ergotaman-3,6,18-trione, 9,10-dihydro-12-hydroxy-2-methyl-5-(phenylmethyl)-, (5.alpha.,10.alpha.)-, monomethanesulfonate but generally known as dihydroergotamine, which bears US NIH Compound Identifier 3066.

UNSPSC 51142404 Dihydroergotamine is a Commodity code that nominally covers a specific ergot-alkaloid pharmaceutical, but recent state and local procurement activity shows no substantive buying under this code. The three most recent opportunities posted under this code — Seminole County's Naloxone and Drug Deactivation Systems IFB (June 2026), Texas HHS Commission's Therapeutic Pharmacy Initiative Direct-to-Manufacturer RFI (April 2026), and Minnesota MMCAP's Generic Multi-Source Pharmaceuticals RFP (January 2026) — are all pharmaceutical and health-supply procurement but do not center on dihydroergotamine itself. The Seminole County solicitation specifically seeks naloxone and drug deactivation systems; the Texas RFI explores direct-to-manufacturer prescription channels without naming dihydroergotamine; and the MMCAP RFP addresses generic multi-source drugs and OTC products across a multi-state cooperative purchasing vehicle without specifying dihydroergotamine as a line item. The mismatch between the code's nominal scope and the actual work being tagged suggests either category-assignment drift in the posting systems or limited recent demand for dihydroergotamine specifically.

Activity across the three opportunities spans county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing administered by a state procurement office (Minnesota Department of Administration). The geographic spread includes Florida, Texas, and Minnesota with extensions to Oregon through the MMCAP vehicle. The Seminole County opportunity is an IFB with a response deadline of July 26, 2023 (note: date appears inconsistent with June 2026 posting); the Texas RFI closed April 3, 2026 and is information-gathering rather than a binding solicitation; and the Minnesota MMCAP RFP closed March 26, 2026 and establishes multiple contracts across authorized pharmaceutical wholesalers effective July 1, 2026. Firms tracking dihydroergotamine procurement specifically should monitor whether future state and local pharmaceutical buys tag this code accurately or continue to list it alongside broader drug-supply initiatives.